Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AKT”

142 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 142 results

Testing effectiveness (Phase 2)Study completedNCT02162719
What this trial is testing

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

Who this might be right for
Breast Neoplasms
Genentech, Inc. 124
Testing effectiveness (Phase 2)WithdrawnNCT01445587
What this trial is testing

GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Who this might be right for
Cancer
GlaxoSmithKline
Testing effectiveness (Phase 2)Ended earlyNCT01466868
What this trial is testing

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma
Centre Leon Berard 22
Testing effectiveness (Phase 2)Study completedNCT01258998
What this trial is testing

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+33 more
National Cancer Institute (NCI) 60
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Early research (Phase 1)Study completedNCT01971515
What this trial is testing

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumor
EMD Serono 101
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Not applicableActive Not RecruitingNCT04615819
What this trial is testing

Access to Kidney Transplantation in Minority Populations

Who this might be right for
Kidney Diseases
University of New Mexico 376
Early research (Phase 1)Study completedNCT01783171
What this trial is testing

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Who this might be right for
Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage III Pancreatic Cancer AJCC v6 and v7+2 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)UnknownNCT02430363
What this trial is testing

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Who this might be right for
Glioblastoma
Medical Research Council 58
Testing effectiveness (Phase 2)Ended earlyNCT01907815
What this trial is testing

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
Recurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Study completedNCT01604772
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

Who this might be right for
Recurrent Oral Cavity Adenoid Cystic CarcinomaRecurrent Salivary Gland CarcinomaSalivary Gland Adenoid Cystic Carcinoma+6 more
National Cancer Institute (NCI) 16
Early research (Phase 1)Study completedNCT01428492
What this trial is testing

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis 90
Testing effectiveness (Phase 2)Looking for participantsNCT06463028
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Faeth Therapeutics 40
Testing effectiveness (Phase 2)Ended earlyNCT02644122
What this trial is testing

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Ezra Cohen 1
Not applicableWithdrawnNCT05597982
What this trial is testing

How Do Structural Social Determinants of Health Affect AKT-MP and Outcomes

Who this might be right for
Kidney DiseasesSocial Determinants of Health
University of New Mexico
Early research (Phase 1)Study completedNCT01476137
What this trial is testing

The Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Who this might be right for
Cancer
GlaxoSmithKline 335
Testing effectiveness (Phase 2)Active Not RecruitingNCT06400251
What this trial is testing

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439123
What this trial is testing

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT01307631
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell Adenocarcinoma+2 more
National Cancer Institute (NCI) 37
Load More Results